Literature DB >> 19109477

Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host.

Arlo Upton1, Andrew Woodhouse, Ross Vaughan, Sandie Newton, Rod Ellis-Pegler.   

Abstract

We report a case of disseminated isoniazid-resistant tuberculosis in an immunocompromised patient with evolution of rifampin (rifampicin) resistance in the central nervous system. This was cured with intraventricular and oral treatment but was followed by a late relapse of the original infection in a prosthetic hip joint. We provide drug levels in cerebrospinal fluid and serum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109477      PMCID: PMC2643679          DOI: 10.1128/JCM.01473-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.

Authors:  S E Berning; T A Cherry; M D Iseman
Journal:  Clin Infect Dis       Date:  2001-02-09       Impact factor: 9.079

2.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.

Authors:  P Barco; R F Cardoso; R D C Hirata; C Q F Leite; J R Pandolfi; D N Sato; M L Shikama; F Fiúza de Melo; E M Mamizuka; P A Z Campanerut; M H Hirata
Journal:  J Antimicrob Chemother       Date:  2006-09-13       Impact factor: 5.790

3.  The rise and spread of drug-resistant tuberculosis.

Authors: 
Journal:  Lancet       Date:  2008-03-01       Impact factor: 79.321

4.  Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications.

Authors:  J P DeVincenzo; S E Berning; C A Peloquin; R N Husson
Journal:  Ann Pharmacother       Date:  1999-11       Impact factor: 3.154

5.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 6.  Using therapeutic drug monitoring to dose the antimycobacterial drugs.

Authors:  C A Peloquin
Journal:  Clin Chest Med       Date:  1997-03       Impact factor: 2.878

7.  Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin.

Authors:  R Rossau; H Traore; H De Beenhouwer; W Mijs; G Jannes; P De Rijk; F Portaels
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 8.  Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis.

Authors:  R J Spinner; D J Sexton; R D Goldner; L S Levin
Journal:  J Arthroplasty       Date:  1996-02       Impact factor: 4.757

9.  Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis.

Authors:  G A Ellard; M J Humphries; B W Allen
Journal:  Am Rev Respir Dis       Date:  1993-09

10.  Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

Authors:  Mathias W R Pletz; Andres De Roux; Andreas Roth; Karl-Heinz Neumann; Harald Mauch; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  3 in total

Review 1.  Tubercular prosthetic joint infection: two case reports and literature review.

Authors:  Sara Veloci; Jessica Mencarini; Filippo Lagi; Giovanni Beltrami; Domenico Andrea Campanacci; Alessandro Bartoloni; Filippo Bartalesi
Journal:  Infection       Date:  2017-10-30       Impact factor: 3.553

2.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

3.  Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness.

Authors:  Russell R Kempker; Alison G C Smith; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Shorena Sabanadze; Zaza Avaliani; Jeffrey M Collins; Henry M Blumberg; Mohammad H Alshaer; Charles A Peloquin; Maia Kipiani
Journal:  Clin Infect Dis       Date:  2022-09-10       Impact factor: 20.999

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.